WHC is still in active development. Read this to understand our approach.
depiction of CEUORZQYGODEFX-UHFFFAOYSA-N.svg
isomerdesign

Aripiprazole

Verificar en isomerdesign

pubchem

Aripiprazole

Verificar en pubchem

drugmap

Aripiprazole

Verificar en drugmap

wiki

Aripiprazole

Verificar en wiki

Data

InChI: InChI=1S/C23H27Cl2N3O2/c24-19-4-3-5-21(23(19)25)28-13-11-27(12-14-28)10-1-2-15-30-18-8-6-17-7-9-22(29)26-20(17)16-18/h3-6,8,16H,1-2,7,9-15H2,(H,26,29)

Sinónimos: ARIPIPRAZOLE [ORANGE BOOK],SCHEMBL8255,CHEMBL1112, C23H27Cl2N3O2,7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one,MFCD00892072,7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1H)-quinolinone,Abilify MyCite,A19454,OPC 31,BCP9000317,J-005707,Aripiprazole solution, 1.0 mg/mL (50:50 Methanol/Water with 1% 1N HCl), ampule of 1 mL, certified reference material, Pripiprazole, Aripiprazole/escitalopram fixed-dose combination,129722-12-9,Aripiprazole 1.0 mg/ml in Acetonitrile, 7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one,MLS006011892,NSC-759266,7-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril, OPC-14597,GTPL34,AKOS005558247,Aripiprazole [USAN],SCHEMBL5335696,Z1521553846, HSDB 7320, OPC 14597,Aripiprex,SBI-0206870.P001,s1975, Aripiprazole (JAN/USAN/INN), 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydro-2(1H)-quinolinone,Abilify Digital,NC00141, 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1H)-quinolinone,722A129,FT-0662279,NSC759266,BRD-K70358946-001-06-6,ARIPIPRAZOLE [INN],ARIPIPRAZOLE [HSDB],BBL029082,7-[4-(4-(2,3-Dichlorophenyl)piperazin-1-yl)butoxy]-3,4-dihydro-2(1H)-quinolinone,HMS2230M18,129722-12-9 (free base), 7-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril,HMS2089M20,7-{4-[4-(2,3-dichlorophenyl)piperazino]butoxy}-3,4-dihydro-2(1H)-quinolinone,Aripiprazole, Discmelt (TN),NCGC00159510-03,BA164218,DSSTox_CID_26083, Abilify,7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3, 4-dihydrocarbostyril,Discmelt,7-{4-[4-(2,3-Dichloro-phenyl)-piperazin-1-yl]-butoxy}-3,4-dihydro-1H-quinol in-2-one, Aripiprazole [USAN],BMS-337039,Aristada (aripiprazole lauroxil),aripiprazol, Abilify,82VFR53I78,Pharmakon1600-01505851,AM20090766,NCGC00159510-04,ARIPIPRAZOLE [USP-RS],Aripiprazole (Abilify),MLS001165779,1026778-41-5,FT-0600352,7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-quinolin-2(1H)-one,SR-01000759353,Q411188,7-(4-[-(2,3-Dichlorphenyl)piperazin-1-yl]butoxy)-3,4-dihydrochinolin-2(1H)-one,7-(4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy)-3,4-dihydrocarbostyril,7-{4-[-4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3,4-dihydrocarbostyril,MLS000759517,AB07660,BDBM50130293,SY053146, OPC 31,Abilify (TN),Aripiprazole (JAN/USP/INN),STK625160,Aripiprazole-d8(butyl-d8), Bristol-Myers Squibb brand of aripiprazole, Arpizol,Tox21_111728,DSSTox_RID_81324,HMS3393I18, ALKS-9070,MLS001424078,HMS3373D04,AB00639935-09, Aripiprazolum,ARIPIPRAZOLE [USP MONOGRAPH], 7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one,7-(4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy)-3,4-dihydroquinolin-2(1H)-one,AB00639935_10,ARIPIPRAZOLE [WHO-DD], Otsuka brand of aripiprazole,Aripiprazole solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material,Abilify OD,OPC-14597, 7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-1,2,3,4-tetrahydroquinolin-2-one,L001339, 7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydrocarbostyril,HMS2051I18,ZINC1851149,UNII-82VFR53I78,Aripiprazole [USAN:INN:BAN],7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydrocarbostyril,CPD000466383,AB00639935_11,DSSTox_GSID_46083,HMS3657K13,EN300-119521,9SC,KS-1030,NCGC00159510-05,DL-178,SCHEMBL12961254,HMS3744A13,7-(4-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)BUTOXY)-3,4-DIHYDROQUINOLIN-2(1H)-ONE, Discmelt,2(1H)-Quinolinone, 7-(4-(4-(2,3-dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydro-, Aripirazole,7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydro-2(1H)-quinolinone,CS-0766,HMS2093F22, Aripiprazol,Abilify,7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one, Abilitat,Opc 14597,ARIPIPRAZOLE [MI],Abilify Maintena Kit,aripiprazolum, S06-0010,SMR000466383,DB01238, OPC-31,Abilify Discmelt,7-{4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy}-3,4-dihydrocarbostyril, BMS-337039,HSDB 7320,DTXSID3046083,Aripiprazole solution,Aripiprazole Depot, CHEMBL1112,HMS3884E18, ALKS9070/ALKS9072,CCG-100891, 7-(4-(4-(2,3-DICHLOROPHENYL)PIPERAZIN-1-YL)BUTOXY)-3,4-DIHYDROQUINOLIN-2(1H)-ONE,ACT03221, CHEBI:31236,SW197521-3, Abilify (TN),D01164,SR-01000759353-6,NSC 759266, UNII-82VFR53I78,CHEBI:31236,7-[4-[4-(2,3-Dichlorophenyl)-1-Piperazinyl]Butoxy]3,4-Dihydro-2(1H)-Quinolinone,SR-01000759353-4,7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-1,2,3,4-tetrahydroquinolin-2-one,Abilitat,BCP04902,Tox21_111728_1,7-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydro-2(1H)-quinolinone,AC-1554,FT-0662278, Abilify Discmelt,CAS-129722-12-9, KS-1030,aripiprazole; 7-(4-(4-(2,3-dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydrocarbostyril, Opc 14597,7-[4-[4-[2,3-bis(chloranyl)phenyl]piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one,ARIPIPRAZOLE [MART.],NCGC00159510-02,OPC-31,Aripiprazole-d8 solution,ARIPIPRAZOLE [EMA EPAR],Aripiprazole- Bio-X,Abilify Maintena,ARIPIPRAZOLE [JAN],ARIPIPRAZOLE [EP MONOGRAPH], Asprito,HY-14546,ABILIFY MYCITE KIT,MLS001195621,HMS3715J07,24-29-3,7-{4-[4-(2,3-Dichloro-phenyl)-piperazin-1-yl]-butoxy}-3,4-dihydro-1H-quinolin-2-one,ARIPIPRAZOLE [VANDF],2(1H)-Quinolinone, 7-[4-[4-(2,3-dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydro-


Estimated data

Solubilidad: -4.761 (log(S) in mol/L prediction using SolTranNet)

Blood Brain Barrier Permeability: Yes (prediction using frontiersin.org)

Addictivity Prediction: 33.5% (prediction based on www.mdpi.com)

Similitudes

The following is a set of comparisons to understand the properties of this compound. This is still higly experimental and is still under active development. Please refer to our series of blog posts to fully understand our approach and its limitations. This information is for informational purposes only and should not be construed as medical advice.